Skip to main content

Table 1 Clinical characteristics

From: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

 

Total

Training cohort

 

Validation cohort

 

P

  

Total

Patients, NO. (%)

P

Total

Patients, NO. (%)

P

 

Characteristic

  

A+T

T

 

A+T

T

 

NO. of patients

318

176

88

88

 

142

71

71

  

Median age, years (range)

56 (28–83)

56 (28–83)

55.75 (28–74)

57 (31–84)

0.166

 

56 (26–75)

57 (33–80)

0.412

0.735

Sex

 Male

128 (40.2%)

67 (38.1%)

36 (40.9%)

31 (35.2%)

0.535

61 (43%)

30 (42.3%)

31 (43.7%)

0.768

0.744

 Female

190 (59.8%)

109 (61.9%)

52 (59.1%)

57 (64.8%)

 

81 (57%)

41 (57.7%)

40 (56.3%)

  

Smoking history

 Never

232 (73%)

121 (68.8%)

66 (75%)

55 (62.5%)

0.103

111 (78.2%)

56 (78.9%)

55 (75%)

0.925

0.417

 Former

86 (27%)

55 (31.2%)

22 (25%)

33 (37.5%)

 

31 (21.8%)

15 (21.1%)

16 (25%)

  

Pathology

 Adenocarcinoma

318 (100)

176 (100%)

88 (100%)

88 (100%)

1

142 (100%)

71 (100%)

71 (100%)

1

1

 Squamous carcinoma

0

0 (0%)

0 (0%)

0 (0%)

 

0 (0%)

0 (0%)

0 (0%)

  

ECOG performance status

 0–1

303 (94.3%)

172 (97.7%)

86 (97.7%)

86 (97.7%)

1

131 (92.2%)

65 (91.5%)

66 (92.9%)

0.975

0.896

 2

15 (5.7%)

4 (2.3%)

2 (2.3%)

2 (2.3%)

 

11 (7.3%)

6 (8.5%)

5 (7.1%)

  

Brain metastasis

 Yes

102 (32%)

58 (32.9%)

28 (31.8%)

30 (34.1%)

0.862

44 (30.9%)

23 (32.4%)

21 (29.5%)

0.769

0.711

 No

216 (68%)

118 (67.1%)

60 (68.2%)

58 (65.9%)

 

98 (69.1%)

48 (61.6%)

50 (70.5%)

  

Bone metastasis

 Yes

160 (50.3%)

88 (50%)

47 (53.4%)

41 (46.6%)

0.451

72 (50.7%)

34 (47.9%)

38 (53.5%)

0.379

0.637

 No

158 (49.7%)

88 (50%)

41 (46.6%)

47 (53.4%)

 

69 (49.3%)

37 (52.1%)

33 (46.5%)

  

Liver metastasis

 Yes

40 (12.5%)

21 (11.9%)

12 (13.6%)

9 (10.2%)

0.643

19 (13.4%)

9 (12.6%)

10 (14.1%)

0.563

0.677

 No

278 (87.5%)

155 (88.1%)

76 (86.4%)

79 (89.8%)

 

123 (86.6%)

62 (87.4%)

61 (85.9%)

  

Stage

 IIIa/IIIb

9 (2.8%)

5 (2.8%)

1 (1.1%)

4 (4.5%)

0.368

4 (2.8%)

2 (1.1%)

2 (4.5%)

1

0.614

 IV

309 (97.2%)

171 (97.2%)

87 (98.9%)

84 (95.5%)

 

138 (97.2%)

69 (98.9%)

69 (95.5%)

 Â